trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

In 2025 the European Medicines Agency's safety committee concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 2 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that in 2025 the European Medicines Agency's safety committee concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide?

Yes. The European Medicines Agency's own 6 June 2025 announcement states that its safety committee (PRAC) concluded NAION is a very rare side effect of semaglutide medicines. A commentary's reference list also cites that EMA conclusion, while later reviews dispute causality but do not address what PRAC concluded.

Verdict: SUPPORTED · 3 sources for, 2 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 3
Emerging risk of non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide: a safety alert for clinicians -
Get citation
Emerging risk of non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide: a safety alert for clinicians - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://doi.org/10.1097/MS9.0000000000004914

Evidence against · 2
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.
2026
Get citation
N, E. & O, B. (2026). Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.. doi.org. https://doi.org/10.1016/j.aed.2026.01.001

See more details
More for · 2
PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA)
Get citation
PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA). (n.d.). ema.europa.eu. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy

Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) - GOV.UKGOV.UK
Get citation
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) - GOV.UKGOV.UK. (n.d.). gov.uk. https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion

More against · 1
Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.
2026
Get citation
FA, A., MA, A., YB, A., AK, A., AA, A., MA, A., M, A., SA, A., SM, A., & AY, A. (2026). Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.. doi.org. https://doi.org/10.1002/acn3.70406

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work